Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Accelerometer-based activity using tri-axial (Axivity, UK) accelerometers |
The patients will have an accelerometer sensor mounted with tape to both upper arms for 4 days. The sensors will measure 24/7 activity of the upper arms. |
Measured at baseline and 12-month follow-up |
|
Other |
Accelerometer-based degree of movement using tri-axial (Axivity, UK) accelerometers |
The patients will have an accelerometer sensor mounted with tape to both upper arms for 4 days. The sensors will measure 24/7 degree of movement. |
Measured at baseline and 12-month follow-up |
|
Other |
The 100 mm Visual Analogue Scale (exercise-group) |
Patient reported pain intensity at rest. With a possible score ranging from 0 to 100, with 100 indicating the worst possible pain. |
Measured immediately before and immideately after each exercise session. From the date of the start of the exercise intervention until the end of the exercise intervention, assessed up to 12 months. |
|
Other |
EuroQol Group 5-dimension 5-level (EQ-5D-5L) |
The EuroQol measures the five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. Each dimension consists of one item, distinguished in five levels. We will used the UK value set in this study, because a Danish value set is not yet available. These values range from -0.285 to 1.0, a value of 1.0 corresponds to full health, 0 corresponds to death and negative values correspond to health status considered to be worse than death. |
Measured at baseline, 12-week, 12-month, 2- 5- and 10-year follow-up. |
|
Other |
Productivity Costs Questionnaire (iPCQ) |
The iPCQ is a questionnaire for the measurement of costs in economic evaluations. It consists of 18 questions of which 9 are general questions followed by questions to measure productivity losses of paid work due to 1) absenteeism and 2) presenteeism and productivity losses related to 3) unpaid work. The minimum value is 0 (no productivity loss) and the maximum value is infinite. Measured for the health economic evaluation in Denmark. |
Measured at 12-week and 12-month. |
|
Other |
Patient Acceptable Symptom State (PASS) |
PASS will be assessed with the following question, reported by the patient: "When you think of your shoulder function, will you consider your current condition as satisfying? By shoulder function, you should take into account your activities of daily living, sport and recreational activities, your shoulder pain and other symptoms and your quality-of-life", measured on a dichotomous scale (yes/no). |
Measured at 12-month, 2-, 5- and 10-year follow-up. |
|
Other |
Treatment Failure |
Patient-reported treatment failure will be assessed only by patients answering "no" to PASS with the following question: "Would you consider your current state as being so unsatisfactory that you think the treatment has failed?" on a dichotomous scale (yes/no). |
Measured at 12-month, 2-, 5- and 10-year follow-up. |
|
Other |
Number of total shoulder arthroplasty surgeries (exercise-group) |
Number of total shoulder arthroplasty surgeries performed in the exercise-group. |
Measured from baseline to 12-month, 2-, 5- and 10-year follow-up. |
|
Other |
Number of supervised exercise sessions from baseline to 3 months (exercise-group) |
High compliance will be defined as participation in =70 percent of the training sessions; moderate compliance as participation in 50-70 percent of the sessions; and poor compliance as participation in <50 percent of the sessions. |
From baseline to 12-week |
|
Other |
Number of patients performing unsupervised exercise (exercise-group) |
Adherence to two weekly unsupervised exercise sessions will be measured by a patient-reported questionnaire |
From baseline to 12-week |
|
Other |
Number of patients performing unsupervised exercise (exercise-group) |
Adherence to optional unsupervised exercise sessions will be measured by a patient-reported questionnaire |
From 12-week to 12-month |
|
Primary |
the Western Ontario Osteoarthritis of the Shoulder index (WOOS) |
WOOS consist of 19 items to be answered using a visual analog scale (VAS). Each item has a possible score ranging from 0 to 100, leading to a total WOOS score ranging from 0 to 1900, with 0 being the best. For simplicity reasons, raw scores can be converted to a percentage of the maximum score (0-100, 100 best). |
Measured at 12 month follow-up |
|
Secondary |
the Western Ontario Osteoarthritis of the Shoulder index (WOOS) |
WOOS consist of 19 items to be answered using a visual analog scale (VAS). Each item has a possible score ranging from 0 to 100, leading to a total WOOS score ranging from 0 to 1900, with 0 being the best. For simplicity reasons, raw scores can be converted to a percentage of the maximum score (0-100, 100 best). |
Measured at baseline, 12-week, 2-, 5- and 10-year follow-up |
|
Secondary |
Disabilities of the Arm, Shoulder and Hand (DASH) |
DASH is a self-administered questionnaire that consist of thirty core items and eight items assessing work and sports and/or performing arts activities. Each individual item is scored on a 5-point Likert scale, and lower scores correlated to minimal impairments and higher scores indicate more impairment. The cumulative DASH score is scaled from 0-100 with higher scores indicating more disability |
Measured at baseline, 12-week, 12-month, 2-, 5- and 10-year follow-up |
|
Secondary |
The change in pain measured on a 100 mm Visual Analogue Scale (VAS) |
Patient reported pain intensity at rest, during activity and nightly pain. With a possible score ranging from 0 to 100, with 100 indicating the worst possible pain |
Measured at baseline, 12-week, 12-month, 2-, 5- and 10-year follow-up |
|
Secondary |
The use of analgesics during the last week |
The patients will be asked if they take any analgesics (yes/no) |
Measured at baseline, 12-week, 12-month, 2-, 5- and 10-year follow-up |
|
Secondary |
The type of analgesics consumed during the last week |
The patients will be asked which type of analgesics they take (paracetamol, NSAID, morphine/opioids). |
Measured at baseline, 12-week, 12-month, 2-, 5- and 10-year follow-up |
|
Secondary |
Consumption of analgesics during the last week |
The patients will be asked how often they consume the analgesic medication (never, daily, weekly, monthly). |
Measured at baseline, 12-week, 12-month, 2-, 5- and 10-year follow-up |
|
Secondary |
Serious Adverse Events |
Serious adverse events are defined as embolism (cardiac or brain), death, liver and renal failure. |
The patients in the surgical intervention group will be monitored for serious adverse events during the 4 weeks from the discharge. |
|
Secondary |
Adverse events |
Defined as any unintended and unfavorable sign, symptom or disease resulting in contact with the healthcare system irrespective of a causal relationship with the intervention and outcome assessments. |
Occurring during the period from inclusion until the 12-month follow-up |
|